Archiv - Juni 2009
Serum levels of the adipokine FGF21 depend on renal function.
Stein S, Bachmann A, Lössner U, Kratzsch J, Blüher M, Stumvoll M, Fasshauer M.
University of Leipzig, Department of Internal Medicine III, Leipzig, Germany
Diabetes Care. 2009 Jan;32(1):126-8.
OBJECTIVE: To investigate renal elimination of the adipokine fibroblast growth factor 21 (FGF21) by determining circulating FGF21 levels in patients on chronic hemodialysis (CD) as compared with control subjects with a glomerular filtration rate (GFR) >50 ml/min. RESEARCH DESIGN AND METHODS: FGF21 was determined by enzyme-linked immunosorbent assay in control (n = 60) and CD (n = 60) patients and correlated to clinical and biochemical measures of renal function, glucose and lipid metabolism, and inflammation in both groups. RESULTS: Median serum FGF21 levels were >15-fold higher in CD patients (3,710.6 ng/l) than in subjects with a GFR >50 ml/min (201.9 ng/l) (P < 0.001). Furthermore, serum creatinine positively and GFR negatively predicted FGF21 concentrations in multiple regression analyses in control subjects (P < 0.05). CONCLUSIONS: FGF21 serum levels increase in CD patients and are related to markers of renal function in control subjects.